Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 4/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.39 |
| ▸ | USP2 | O75604 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | CCR2 | P41597 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26429301 | 1.00 | CHRM2 (0.42) | CHRM2CHRM1CHRM5CHRM3HDAC1 | |
| SCHEMBL26429293 | 1.00 | CHRM2 (0.42) | CHRM2CHRM1CHRM5CHRM3HDAC1 | |
| SCHEMBL30345685 | 1.00 | CHRM2 (0.42) | CHRM2CHRM1CHRM5CHRM3HDAC1 | |
| SCHEMBL26431387 | 0.88 | CHRM2 (0.51) | CHRM2CHRM1CHRM5CHRM3HDAC1 | |
| SCHEMBL23744264 | 0.88 | CHRM2 (0.51) | CHRM2CHRM1CHRM5CHRM3HDAC1 | |
| SCHEMBL26429291 | 0.85 | CHRM2 (0.48) | CHRM2CHRM1CHRM5CHRM3HDAC1 | |
| SCHEMBL26429443 | 0.85 | CHRM2 (0.48) | CHRM2CHRM1CHRM5CHRM3HDAC1 | |
| SCHEMBL30345578 | 0.85 | CHRM2 (0.46) | CHRM2CHRM1CHRM5CHRM3HDAC1 | |
| SCHEMBL30345510 | 0.85 | CHRM2 (0.46) | CHRM2CHRM1CHRM5CHRM3HDAC1 | |
| SCHEMBL26090288 | 0.85 | CHRM2 (0.46) | CHRM2CHRM1CHRM5CHRM3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | CHRM4, CHRM2, CHRM5 | CHRM2 2/4885CHRM1 5/4885CHRM5 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.